Abbott Agrees to Pay Over $384M to Settle Allegations Related to Contaminated Infant Formula

The record

Publisher

U.S. Department of Justice

Source

U.S. Department of Justice

Kind

Release

Jurisdiction

United States

Topics

Enforcement

Importance

Notable, the middle of three tiers Kresmion sets by fixed rules from the source's own fields

Published (source time)

2026-09-14 12:00 UTC

First seen on Kresmion

2026-09-14 16:00 UTC, 4 h after publication

The original

Link checked 2026-10-27: available.

Source: U.S. Department of Justice. U.S. Government work.

The publisher's summary

Abbott Laboratories (Abbott), an Illinois-based healthcare company that manufactures and sells infant formula and nutritional therapy products, has agreed to pay $384,999,040 to resolve allegations that it caused false claims to be submitted between Jan. 1, 2018, and Dec. 31, 2022, to federal and state programs arising from its failure to manufacture certain powder infant formula and nutritional therapy products at its Sturgis, Michigan, and Casa Grande, Arizona, facilities in compliance with federal and state statutory, regulatory, and contractual requirements.

The publisher's words, as published.